Coherent, Inc. Receives FDA Clearance for Dermatological Laser
April 9, 1996
No. # 555
Coherent Inc., Santa Clara, CA, (NASDAQ: COHR) announced today its Medical
Group in Palo Alto, CA, received Food and Drug Administration clearance
to market its new multi-wavelength VersaPulse Aesthetic laser. Featuring
four separate wavelengths, the VersaPulse can be used for the removal of
tattoos and treatment of both vascular and pigmented lesions, such as birthmarks,
port wine stains, and "telangiectasias," the unsightly veins of the legs
and face.
The VersaPulse Aesthetic laser is a significant advance in aesthetic laser
performance. Physicians currently use up to four separate laser systems to
achieve the capabilities offered by a single VersaPulse laser. New laser
technology developed at Coherent allows treatment of lesions containing
larger vessels that often do not respond to conventional lasers.
The VersaPulse Aesthetic laser was unveiled at the recent American Academy
of Dermatologists meeting in Washington, D.C., and attracted significant
attention from the surgical community. It is the perfect partner for
Coherent's breakthrough UltraPulse laser-the acknowledged performance
standard for skin resurfacing. Together, they offer the aesthetic surgeon
a World Class Laser
Center.
The Coherent VersaPulse Aesthetic surgical laser and related accessories
are cleared for use in procedures requiring the ablation, vaporization,
excision, incision, and photothermolysis (photocoagulation, or coagulation)
of soft tissue in medical specialties including: dermatology, plastic surgery,
and general surgery.
Coherent lasers are now used in virtually every surgical specialty, including
ophthalmology, aesthetic surgery, orthopedics, urology, gynecology, sinus and
general surgery. New applications continue to be evaluated. Medical lasers are
in the forefront of minimally invasive surgery for improved patient care and
lower cost health care.
Coherent is recognized as a world leader in the design, manufacture and marketing
of lasers and systems for medical, scientific, OEM and micromachining applications.
Please direct any questions to Robert J. Quillinan, Vice President and Chief
Financial Officer at (408)764-4168. For more
information about Coherent, visit our Web site at cohr.com. |
